Soleno Therapeutics Changes Independent Auditor

Ticker: SLNO · Form: 8-K · Filed: 2025-04-18T00:00:00.000Z

Sentiment: neutral

Topics: auditor-change, administrative

TL;DR

Solen Therapeutics swapped auditors from BDO USA to PwC, effective April 17, 2025.

AI Summary

On April 17, 2025, Soleno Therapeutics, Inc. filed an 8-K report to disclose a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm, replacing BDO USA, LLP. This change is effective immediately.

Why It Matters

A change in auditor can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, potentially impacting investor confidence.

Risk Assessment

Risk Level: low — This filing is a routine administrative change regarding the company's auditor and does not inherently present new financial or operational risks.

Key Players & Entities

FAQ

Why did Soleno Therapeutics, Inc. change its certifying accountant?

The filing states that the change was made by the company and does not indicate any disagreements with BDO USA, LLP.

Who is the new independent registered public accounting firm for Soleno Therapeutics, Inc.?

PricewaterhouseCoopers LLP has been appointed as the new independent registered public accounting firm.

Who was the previous independent registered public accounting firm?

The previous independent registered public accounting firm was BDO USA, LLP.

When was the change in certifying accountant effective?

The change was effective as of April 17, 2025.

Were there any disagreements between Soleno Therapeutics and BDO USA, LLP?

The filing explicitly states that there were no disagreements between Soleno Therapeutics, Inc. and BDO USA, LLP.

From the Filing

0001193125-25-085810.txt : 20250418 0001193125-25-085810.hdr.sgml : 20250418 20250418171056 ACCESSION NUMBER: 0001193125-25-085810 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250417 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250418 DATE AS OF CHANGE: 20250418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 25850867 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d935959d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-04-17 2025-04-17     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       ITEM 4.01 Changes in Registrant’s Certifying Accountant Based on information provided by Marcum LLP (Marcum), the former independent registered public accounting firm of Soleno Therapeutics, Inc. (the Company), CBIZ CPAs P.C. (CBIZ CPAs) acquired the relevant business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 17, 2025. On April 17, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and on April 18, 2025, CBIZ CPAs was engaged to serve as the independe

View on Read The Filing